We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Addresses Generic Drug CRL Responses, Orange Book Questions in New Final Guidances
FDA Addresses Generic Drug CRL Responses, Orange Book Questions in New Final Guidances
In a pair of final guidances published Friday, the FDA outlined acceptable reasons for requesting an extension for responding to a Complete Response Letter (CRL) and provided answers to frequently asked questions about the Orange Book, the agency’s reference text for generic drug substitutions.